Intra-Arterial Hepatic Chemoembolization in Liver Metastases from Neuroendocrine Tumors: A Phase II Study

• DOI: 10.1179/joc.2004.16.3.293
• Publication Date: 2014-01-09T18:05:28Z
• Authors: G. Fiorentini; S. Rossi; F. Bonechi; M. Vaira; M. De Simone; P. Dentico; P. Bernardeschi; M. Cantore; S. Guadagni
• Keywords: Lipiodol; Carcinoid tumors

AbstractNeuroendocrine tumors, particularly those of gastrointestinal tract origin, have a predisposition for metastasizing to the liver, causing parenchymal substitution and paraneoplastic syndrome. Lipiodol embolization combined with anticancer drugs is recent tool in regional therapy. It has been proven that chemoembolization reduces tumor bulk hormone levels, it palliates symptoms many patients liver-dominant neuroendocrine metastases. Beginning December 1988, ten unresectable chemotherapy-refractory liver metastatic tumors were treated based on mixture lipiodol, mitomycin, cisplatin, epirubicin, followed by gelfoam powder contrast media. Toxicity encountered included: upper right quadrant pain requiring narcotics, elevation lactate dehydrogenase, alkaline phosphatase, transaminases. One patient had abscess persistent fever 2 weeks. We obtained two complete remissions lasting 12 34 months 5 partial remissions. The median survival was 22 months. Four urinary 5-hydroxyindolacetic acid (5-HIAA). They showed more than 75% decrease secretion after treatment. In transplanted we noticed response 7 conclude will improve clinical condition significant percentage metastases, future therapy carcinoid be specific biology treatment customized each individual combining use cytoreductive procedures including radiofrequency ablation, laser chemoembolization.Keywords: Neuroendocrine tumorschemoembolizationliver metastases